- Endovascular stent grafts, used in the minimally invasive treatment of aneurysms and other vascular conditions, are becoming increasingly essential in modern vascular surgery due to their ability to reduce operative trauma, recovery time, and overall complication rates. These devices allow for precise deployment within blood vessels and offer improved outcomes compared to open surgery
- The escalating demand for endovascular stent grafts is primarily fueled by the rising global prevalence of aortic aneurysms, increasing aging population, advancements in imaging and catheter-based technologies, and growing preference for less invasive procedures
- North America dominated the endovascular stent grafts market with the largest revenue share of 38.2% in 2024, supported by a robust healthcare infrastructure, early adoption of innovative vascular technologies, and a high burden of cardiovascular diseases. The U.S. remains the largest contributor within the region, driven by increasing procedure volumes, favorable reimbursement policies, and a strong pipeline of product innovations by key medical device companies
- Asia-Pacific is expected to be the fastest-growing region, with a projected CAGR of 7.9% from 2025 to 2032, owing to increasing healthcare expenditure, expanding patient awareness, and the growing prevalence of lifestyle-related cardiovascular diseases in rapidly urbanizing nations such as China, India, and South Korea
- The Synthetic segment dominated the market with the largest revenue share of 62.5% in 2024, attributed to its widespread availability, cost-effectiveness, and durability. Synthetic stent grafts, typically made of materials such as polyester or expanded polytetrafluoroethylene (ePTFE), are widely used in endovascular aneurysm repair (EVAR) and thoracic endovascular aortic repair (TEVAR) due to their high tensile strength and compatibility with various anatomical structures
